Study Medication  Time schedule  Résumé Development of an improved tablet formulation  Long term stability  Reasonable production conditions  Focus.

Slides:



Advertisements
Similar presentations
Producing a Pharmaceutical or Biopharmaceutical
Advertisements

 AUTHOR- Musiba Baliruno Denis, B.pharm (MUST) SUPERVISORS ;  Prof. K.A.M. Kuria, PhD - Department of Pharmaceutics and Pharmacy Practice, University.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Training Workshop on Pharmaceutical Development.
Annual Product Review (APR) Product Quality Review (PQR)
2-5. Formulation Development Issues: Solid Orals Satish Mallya January, 2011.
Finished Pharmaceutical Product Specifications
By Timina Olive Kayaviri Supervisor : Dr. Amugune
IMP/Placebo Sourcing, Release, Storage and Reconciliation. Ms Caroline Whiriskey Research Pharmacist, HRB Clinical Research Facility Galway.
Manufacturing Process
Module 12 – part 2 | Slide 1 of 35 January 2006 Basic Principles of GMP Documentation Part 2 15.
Tablet Coating Why coat tablets? Types of coatings  sugar coating  film coating  press coating (compression coating) B. Amsden1CHEE 440.
MANUFACTURING PROCESS AND VALIDATION
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Reference, Retention and Reserve Samples
World Health Organization
Page Break 2 + Strap line. About Quay Pharma Provider of contract development and manufacturing services to the pharmaceutical and healthcare industries.
Documentation –Part 2 Basic Principles of GMP Pharmaceutical Quality,
Basic Principles of GMP
PRODUCT TRANSFER.
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
Ms. RIFFAT YASMIN. Objectives Discuss types of Ophthalmic Dosage forms with examples Interpret the Advantages & Disadvantages of : 1. Ophthalmic solutions.
Improved Tablet  Focus on stability  Focus on reasonable production  Focus on packaging material High-End Tablet  Vision?! Study Medication  Focus.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Quality control Lecture 1.
OR “READ THE FINE PRINT PLEASE!”
TECHNICAL REQUIREMENTS FOR MINOR APPLICATIONS E MOKANTLA 3 SEPTEMBER 2013.
Formulation factors By Dr. A. S. Adebayo.
THE BIOTECHNOLOGY WORKPLACE. OVERVIEW Biotechnology workplaces Laboratories.
 Objectives / Deliverables  Strategy  Ideas  First Results  Recent and Next Steps G&H Meeting th April, 2002 Leipzig, Germany WP 7 Pharmaceutics.
30/02/2008 Dept. of Pharmaceutics 1 Salient Features of Quality Assurance Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate Professor Department of Pharmaceutics.
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
DH 29  Development of analytical methods DH 30  Analysis of EU market products DH 33  Development of a novel tablet DH 36  Preparation of study medication.
Formulation, Characterization of Pellets of Duloxetine Hydrochloride by Extrusion and Spheronization Prof. V. R. Sinha University Institute of Pharmaceutical.
Master Formula And Batch MaNUFACTURING Record
Tablets coating.
Module 12 - part 2Slide 1 of 23 WHO - EDM Basic Principles of GMP Documentation Part 2 Part One, 14.
Solid dosage forms Tablets
ISO 9001 COMPANY Dehumidification in the Pharma Industry Solutions from : #1 in Dehumidification.... Worldwide pt. adhi trikarya mandiri Rukan Artha Gading.
Quality control Lecture 1.
 Objectives Improved Tablet  focus on stability  focus on low costs High-End Tablet  maximum dose  controlled release G&H Meeting 1-2 October, 2002.
Quality Assurance of Medicines under Universal Health Coverage Program by Siriwat Tiptaradol (Presenter) Duangporn Abhigantaphand Sooksri Ungboriboonpisal.
Quality Control significance in pharmaceutical industry
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
{ Medical Review Doses and Terminology Part 2.  Solid dosage forms which have been crushed to make a fine powder  Can be used internally or externally.
Department Of Pharmaceutics. PRODUCTION It is a process or procedure of converting a set of inputs, namely men, capital, information & energy into finished.
HOLD-TIME STUDIES.
Physico-chemical Control of Dosage Forms
- Pharmaceutical Equivalence Study
Oral Dosage of Drugs Chapter 10 MAT 119.
Producing a Pharmaceutical or Biopharmaceutical
VxP Pharma The Pharmaceutical Services Company
Solid dosage forms Tablets
Gastrointestinal Absorption: Role of the Dosage Form
Evaluation of tablet Lab 5.
WHO Technical Report Series, No. 953, 2009
Evaluation of tablet Lab 5.
HHM 5014 NUTRACEUTICAL FORMULATION TECHNOLOGY
Quality control Lecture 1.
Objectives… G&H Meeting February, 2003 Liverpool, UK
Selected Calculations in Contemporary Compounding
Producing a Pharmaceutical or Biopharmaceutical
Quality control Lecture 1.
Evaluation of tablet Lab 5.
Producing a Pharmaceutical or Biopharmaceutical
Evaluation of tablet dosage form 3) Friability
RingCap Technology Mrs. Maria Saifee Associate Professor,
Formulation factors By Dr. A. S. Adebayo.
VICH Guidelines on stability: OVERVIEW
GL3 (R) – Stability Testing of New Veterinary Drug Substances and Medicinal Products (+ Annex GL 4 - Requirements for New Dosage Forms)
VICH Guidelines on stability: OVERVIEW
Presentation transcript:

Study Medication  Time schedule  Résumé Development of an improved tablet formulation  Long term stability  Reasonable production conditions  Focus on packaging material G&H Meeting Sep 29 - Oct 2, 2003 Munich, Germany WP 7 Pharmaceutics (Lichtwer Pharma)  Objectives…

Time schedule Time schedule  7 th -8 th WeekProduction Verum & Placebo 7 th -8 th Week  7 th -8 th WeekWriting & Authorisation production protocol 9 th -10 th Week  9 th -10 th WeekWriting Randomisation Plan 12 th Week  9 th -10 th WeekQuality Control Verum & Placebo 13 th Week  10 th -11 th WeekWriting & Authorisation(!) packaging/labelling 12 th Week  12 th WeekPackaging & Labelling 16 th Week  14 th WeekFinal Release & Delivery 22 th Week Final Release & Delivery (first part) 33 th Week Final Release & Delivery (second part)

 Tabletting: Difficulties with the flowability and compressibility of the EU garlic powder  Coating: Everything went fine…  Sugar Coating: Everything went fine…  Release: Full compliance with specifications!  GCP: Minor deviations  Résumé …

Details on Stability Studies Organic film based  Full compliance to ICH-guidelines  Up to seven different packaging materials  Two different dosage forms Aqueous film based  Reformulation of tablet core  Formulation of coating  Establishing aqueous coating procedure

Stability of Commercial Products (Dragees)

Commercial Products (Dragees)

Organic Film Tablets (100 mg)

Organic Film Tablets (300 mg)

 It is possible to prolong shelf life up to 4 times when… 1.the residual humidity of the tablets is limited to 3,5 – 4 % 2.a strictly humidity controlled coating procedure is applied 3.a packaging material providing a 100% humidity barrier is used  It is possible to produce the improved tablets in an economic way (e.g. no freeze drying necessary!)  Concerning the high demands on the water barrier there is no sufficient polymer blister material available  Conclusion Organic Coated Film Tablet I

 Further optimisation is possible to solve… … the poor disintegration time of the 300 mg tablets from up to 45 min to < 30 min … poor robustness of the formulation concerning high speed tabletting … residual organic solvent problem (film coating)  Conclusion Organic Coated Film Tablet II

 Transforming  Transforming… an organic film coated tablet into… an aqueous film coated tablet!  Why? a)More flexible production process b)No organic solvents necessary c)Adaptable at Lichtwer’s Facilities

 Three production scale batches according ICH-Guidelines have been manufactured successfully in Aug 2003  The residual water content of the tablets are 2.6 to 2.8% (limit: 3.5%)  The batches have been packed in PE bottles and COC300 Blister (Alu/Alu blister coming up next)  The batches are stored under 25°C/60%, 30°C/65%, and 40°C/75% conditions  Overview Status Aqueous Coated Tablets

Production Scheme Production Scheme 1.Weighing and Mixing 2.Tabletting 3.Coating suspension 4.Coating 5.In-Process Controls 6.Packaging

Weighting/Mixing

Tabletting

Coating Suspension

Coating

In-Process Control

Packaging (Blister)

The Team you can trust… The Team you can trust… Wolfgang Lüdeke José Galan-Sousa Silvia Striegl Anke Wermann & Anja Müller Anke Wermann & Anja Müller

The Team you can trust… part II The Team you can trust… part II Bianca Beutke Stability Coordination Bianca Beutke Stability Coordination You can‘t get enough stability!

Thank you very much for… !!! !!!